Skelaxin
PronunciationGeneric Name: Metaxalone
Class: Centrally Acting Skeletal Muscle Relaxants
VA Class: MS200
Chemical Name: 5-[(3,5-Dimethylphenoxy)methyl]-2-oxazolidinone
Molecular Formula: C12H15NO3
CAS Number: 1665-48-1
Introduction
Centrally acting skeletal muscle relaxant.b
Uses for Skelaxin
Muscular Conditions
Adjunct to rest, physical therapy, analgesics, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions.101 b
If pharmacologic therapy is required for acute low back pain (usually a benign and self-limiting condition105 106 108 ), an analgesic (e.g., acetaminophen, NSAIA) generally is recommended.104 105 106 108 117 Skeletal muscle relaxants may be used alone or in combination with analgesics for short-term relief; however, consider high incidence of adverse effects (e.g., CNS effects).104 106 107 108 Use skeletal muscle relaxants with caution and weigh risks against benefits.104 106 107 108
Various skeletal muscle relaxants appear to have comparable efficacy for low back pain relief.103 104 106 108
Metaxalone is ineffective in the treatment of skeletal muscle hyperactivity secondary to chronic neurologic disorders (e.g., cerebral palsy) and other dyskinesias.b
Skelaxin Dosage and Administration
Administration
Oral Administration
Administer orally.101
Manufacturer makes no specific recommendations regarding administration with meals; administration with high-fat meal increases absorption, but clinical importance is unknown.101 (See Food under Pharmacokinetics.)
Dosage
Pediatric Patients
Muscular Conditions
Oral
Children >12 years of age: 800 mg 3 or 4 times daily.101 b
Adults
Muscular Conditions
Oral
800 mg 3 or 4 times daily.101 b
Cautions for Skelaxin
Contraindications
Warnings/Precautions
Warnings
CNS Depressants
May enhance the effects of other CNS depressants.101 b (See Specific Drugs and Laboratory Tests under Interactions.)
Sensitivity Reactions
Hypersensitivity Reactions
Possible hypersensitivity reactions.101 b
Specific Populations
Pregnancy
Category B.
Animal studies have failed to reveal fetal risk, but safe use during pregnancy has not been established; do not use in women who are or may become pregnant unless possible benefits outweigh potential risks.101 b
Lactation
Not known whether metaxalone is distributed into milk.101 Use not recommended.101 b
Pediatric Use
Safety and efficacy not established in children ≤12 years of age.101 b
Geriatric Use
Use with caution due to greater frequency of decreased hepatic or renal function and of concomitant disease and drug therapy observed in the elderly.101 b
Hepatic Impairment
Use great caution in patients with a history of liver disease.101 b Perform liver function tests periodically during metaxalone therapy.101 b
Contraindicated in patients with substantial hepatic impairment.101 b
Renal Impairment
Caution advised; contraindicated in patients with substantial renal impairment.101 b
Common Adverse Effects
Drowsiness, dizziness, headache, nervousness or irritability, nausea, vomiting, GI upset.101 b
Interactions for Skelaxin
Specific Drugs and Laboratory Tests
|
Drug or Test |
Interaction |
Comments |
|---|---|---|
|
CNS depressants (e.g., alcohol, barbiturates) |
||
|
Tests for glucose that utilize cupric sulfate (Benedict’s Solution, Clinitest, Fehling’s Solution) |
||
|
Tests for glucose that utilize glucose oxidase (Clinistix, Diastix, Tes-Tape |
Skelaxin Pharmacokinetics
Absorption
Bioavailability
Absolute bioavailability not determined.101
Onset
Usually within 1 hour.b
Duration
About 4–6 hours.b
Food
High-fat meal delays time to peak plasma concentration by about 1–2 hours, increases peak plasma concentration by 178–194%, and increases extent of absorption (AUC) by 115–142%; clinical importance unknown.101
Distribution
Extent
Not known whether metaxalone crosses the placenta or is distributed into milk.101 b
Elimination
Metabolism
Metabolized in the liver.101 b
Elimination Route
Excreted in urine as unidentified metabolites.101 b
Half-life
Stability
Storage
Oral
Tablets
Actions
-
CNS depressant with sedative and skeletal muscle relaxant effects.101 b
-
Precise mechanism of action is not known; does not directly relax skeletal muscle and has minimal skeletal muscle relaxant effect.101 b Beneficial effect probably is related to sedative properties.101 b
-
Unlike neuromuscular blocking agents, does not depress neuronal conduction, neuromuscular transmission, or muscle excitability.b
Advice to Patients
-
Potential for metaxalone to impair mental alertness or physical coordination, especially with concomitant use of alcohol or other CNS depressants; use caution when driving or operating machinery.101 b
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as concomitant illnesses.101 b
-
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.101 b
-
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
|
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
|---|---|---|---|---|
|
Oral |
Tablets |
800 mg |
Skelaxin (scored) |
King |
Comparative Pricing
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2013. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Metaxalone 800MG Tablets (COREPHARMA LLC): 30/$119.99 or 90/$342.97
Skelaxin 800MG Tablets (KING PHARMA): 30/$141.74 or 90/$388.46
Disclaimer
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS Drug Information. © Copyright, 1959-2013, Selected Revisions November 18, 2012. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
References
Only references cited for selected revisions after 1984 are available electronically.
101. King Pharmaceuticals, Inc. Skelaxin (metaxalone) tablets prescribing information. Bristol, TN; 2003 Aug.
103. See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy. 2008; 28:207-13. [PubMed 18225966]
104. van Tulder MW, Touray T, Furlan AD et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev. 2003; :CD004252. [PubMed 12804507]
105. Roelofs PD, Deyo RA, Koes BW et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008; :CD000396. [PubMed 18253976]
106. Chou R, Qaseem A, Snow V et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007; 147:478-91. [PubMed 17909209]
107. Institute for Clinical Systems Improvement. Health care guideline: adult acute and subacute low back pain. 15th ed. Bloomington, MN; 2012 Jan. From the ICSI website
108. Toth PP, Urtis J. Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. Clin Ther. 2004; 26:1355-67. [PubMed 15530999]
117. Boothby LA, Doering PL, Hatton RC. Carisoprodol: a marginally effective skeletal muscle relaxant with serious abuse potential. Hosp Pharm. 2003; 38:337-45.
b. AHFS Drug Information 2006. McEvoy GK, ed. Metaxalone. Bethesda, MD: American Society of Health-System Pharmacists; 2006: 1391-2.
More Skelaxin resources
- Skelaxin Prescribing Information (FDA)
- Skelaxin Consumer Overview
- Skelaxin Advanced Consumer (Micromedex) - Includes Dosage Information
- Skelaxin MedFacts Consumer Leaflet (Wolters Kluwer)
- Metaxalone Prescribing Information (FDA)
- Metaxalone Professional Patient Advice (Wolters Kluwer)




